Company news
Bluenergies Ltd. news in 2006
Bluenergies Ltd.'s news releases, calls and decks from 2006, newest first.
Neurochem announces initial purchaser's exercise of over-allotment option for the purchase of senior convertible notes
November 16, 2006
Neurochem Announces Closing of Private Placement of US$40 Million Aggregate Principal Amount of 6% Senior Convertible Notes with a Conversion Premium of 20%
November 9, 2006
Neurochem reports results for third quarter of fiscal 2006
November 8, 2006
Neurochem to Report on Third Quarter of Fiscal 2006
November 7, 2006
Neurochem receives recommendations from data safety monitoring boards to continue phase III clinical trials for tramiprosate (ALZHEMED(TM))
November 6, 2006
Neurochem Announces Private Placement of US$40 Million Aggregate Principal Amount of 6% Senior Convertible Notes with a Conversion Premium of 20%
November 4, 2006
Neurochem to Present at Upcoming Healthcare Conferences
November 3, 2006
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
November 2, 2006
Neurochem submits a complete response to FDA approvable letter for KIACTA(TM)
October 16, 2006